文献速递其他结缔组织病

系列心脏磁共振监测与免疫抑制治疗预测系统性硬化症结局的评估

Evaluation of serial cardiovascular magnetic resonance monitoring and immunosuppressive therapy in predicting outcomes in systemic sclerosis.
PubMed 文献 · RMD Open · 2026-02-10

本研究纳入44例接受两次心脏磁共振(CMR)扫描的系统性硬化症(SSc)患者,中位随访6.3年,评估CMR参数演变对长期心血管结局的预测价值及免疫抑制治疗对心肌纤维化的影响。结果显示甲氨蝶呤与较低的主要不良心血管事件(MACE)风险相关,利妥昔单抗可降低最大T1值,提示弥漫性心肌纤维化减少。

要点

  • 甲氨蝶呤治疗与SSc患者MACE风险降低相关(p=0.024)。
  • 利妥昔单抗显著降低最大T1值(p=0.029),提示弥漫性心肌纤维化减少。
  • 最大T1值与全因死亡风险增加相关(p=0.044),支持CMR监测的预后价值。

核心结论

  • 甲氨蝶呤与较低的MACE风险相关,利妥昔单抗可降低最大T1值,提示弥漫性心肌纤维化减少,支持CMR监测的预后价值及免疫抑制治疗在SSc相关心脏受累中的潜在获益。

研究设计与样本

  • 单中心研究,纳入44例接受两次相同方案和设备CMR扫描的SSc患者,中位随访6.3年(IQR 3.1-9.2年),两次CMR中位间隔1.5年(IQR 1.0-3.9年)。

主要发现

  • 7例(16%)患者存在舒张功能障碍,16例(36%)患者发生MACE。
  • 利妥昔单抗显著降低最大T1值(p=0.029),最大T1值与全因死亡风险增加相关(p=0.044)。
  • 甲氨蝶呤治疗组左心室射血分数显著增加(p=0.032),且MACE风险较低(p=0.024)。

临床怎么用

  • 对SSc患者可考虑系列CMR监测以评估心肌纤维化进展及心血管风险。
  • 甲氨蝶呤可能降低SSc患者MACE风险,利妥昔单抗可能减少弥漫性心肌纤维化,但需进一步验证。

局限性

  • 单中心小样本研究(44例),结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cardiac involvement is a major complication of systemic sclerosis (SSc), with myocardial fibrosis as a hallmark feature. Cardiovascular magnetic resonance (CMR) is used to detect cardiac involvement. However, the prognostic value of serial CMR monitoring and the effects of immunosuppressive therapy remain unclear. This study aimed to assess the prognostic significance of CMR parameter evolution for long-term cardiovascular outcomes and to evaluate the impact of immunosuppressive treatments on myocardial fibrosis. METHODS: Patients from a single centre who underwent two CMR scans using the same protocol and equipment were included. CMR parameter evolution was compared using paired t-tests. The effects of treatments and changes in CMR parameters on the occurrence of major adverse cardiovascular events (MACE) and mortality were analysed using Kaplan-Meier curves and log-rank tests. RESULTS: 44 patients were included with a median (IQR) follow-up duration of 6.3 (3.1-9.2) years. The median interval between CMR scans was 1.5 (1.0-3.9) years. Seven (16%) patients had diastolic dysfunction, and 16 (36%) patients experienced MACE. Rituximab significantly decreased maximal T1 values (p=0.029), a marker of diffuse myocardial fibrosis linked to an increased risk of all-cause death (p=0.044). A significant increase in left ventricular ejection fraction (p=0.032) and a lower risk of MACE (p=0.024) were observed in patients treated with methotrexate. CONCLUSION: Methotrexate was associated with reduced MACE risk, while rituximab decreased maximal T1 value, suggesting a reduction in diffuse myocardial fibrosis. These findings support the prognostic value of CMR monitoring and the potential benefit of immunosuppressive therapy in SSc-related cardiac involvement.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. Kante A, Mghaeith S, Dunogue B, et al. Evaluation of serial cardiovascular magnetic resonance monitoring and immunosuppressive therapy in predicting outcomes in systemic sclerosis. RMD Open. 2026. PMID: 41667219. doi:10.1136/rmdopen-2025-006562

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。